Lara Kevorkian
UCB Pharma (United Kingdom)(GB)UCB Pharma (Belgium)(BE)
Publications by Year
Research Areas
Protease and Inhibitor Mechanisms, Osteoarthritis Treatment and Mechanisms, Peptidase Inhibition and Analysis, Blood Coagulation and Thrombosis Mechanisms, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → The ADAMTS metalloproteinases(2005)774 cited
- → Expression profiling of metalloproteinases and their inhibitors in cartilage(2004)401 cited
- → Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage(2006)234 cited
- → Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption(2005)188 cited
- → Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer(2016)111 cited
- → Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration(2018)110 cited
- → Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis(2006)87 cited
- → Expression and function of matrix metalloproteinase (MMP)-28(2009)47 cited
- → Characterization and regulation of ADAMTS-16(2009)41 cited
- → MMP28 gene expression is regulated by Sp1 transcription factor acetylation(2010)29 cited